YOKNEAM, Israel, April 5, 2011 /PRNewswire/ -- Syneron Medical
Ltd. (NASDAQ: ELOS), http://www.syneron.com, the global leader in
the medical aesthetic device marketplace, further solidified its
commitment to science, results and earning the trust of aesthetic
physicians with a strong showing of Syneron and Candela's
innovative technologies at the 31st Annual Conference of the
American Society for Laser Medicine and Surgery (ASLMS) in
Grapevine, Texas.
"Our unique combination of cutting-edge science, life-enhancing
clinical results and high level of trust within the global
aesthetic community continues to solidify our position at the
forefront of this industry," said Louis P.
Scafuri, Chief Executive Officer of Syneron. "We value the
opportunity that conferences such as ASLMS provide to showcase our
ability to consistently create and commercialize scientific
advances in innovative medical and aesthetic solutions that meet
our customers' needs."
At the ASLMS conference, Syneron and Candela featured a family
of newly available breakthrough products, including:
-- GentleLASE(R) PRO High Speed Hair Removal System, the Company's latest
and most advanced aesthetic laser. Building on its highly successful
hair removal product line, the next-generation GentleLASE Pro has
been improved to meet the demands of physicians by giving them faster
treatment times, greater treatment versatility and enhanced ease of
use.
According to Thomas E. Rohrer,
MD, Skincare Physicians of Chestnut Hill,
MA, "We have 20 to 30 different lasers, and a lot of these
do hair removal, but we keep ending back at the GentleLASE. It
continues to be my go-to laser for hair removal, no matter how many
hair removal lasers we try."
-- ePrime(TM) Energy-Based Dermal Remodeling System, which was featured
in an experts panel session that was attended by more than 220
physicians interested in learning about this revolutionary new
dimension in facial enhancement. Bypassing the epidermis, ePrime is
the first minimally invasive aesthetic device to precisely target and
deliver measured radio frequency (RF) energy directly into the deep
dermis to stimulate the growth of collagen and elastin for noticeable
improvement of skin tone and volume in a single treatment.
-- elure(TM) Advanced Skin Lightening Technology(TM), the first and only
topical skin lightening product that improves appearance by
temporarily reducing melanin, the pigment that accumulates in the skin
to cause a darkened or uneven skin tone. Using this novel natural
enzyme called Melanozyme(TM), the elure system delivers improvement in
skin appearance, creating healthier, brighter and younger-looking skin
in 30 days, with excellent tolerability.
-- CO2RE(TM) Complete CO2 Resurfacing System, a versatile CO2 system that
offers all current aesthetic CO2 treatment methodologies plus the
unique Fusion fractional mode that has the ability to treat both
superficial and deep skin layers simultaneously with precision-control
over the intensity, pattern and depth of ablation. The introduction of
CO2RE gives customers more choices and greater flexibility to meet
their individual practice needs without the requirement of multiple
hand pieces or optical spots.
-- eMatrix(R) Sublative Rejuvenation(R), the world's first bipolar
RF-only technology for energy-based facial rejuvenation. The device
delivers high-intensity dermal impact with less epidermal ablation,
resulting in minimal patient downtime. Due to the minimal epidermal
disruption, eMatrix treats skin texture and tone without skin color
limitations, making it an ideal rejuvenation choice for patients with
darker skin tones.
In addition to displaying its latest world-class aesthetic
technologies, Syneron had nearly 20 abstracts presented at the
meeting, highlighting the Company's strong commitment to science,
which forms the building blocks to innovate new technology.
For more information, visit http://www.syneron.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. - a company devoted to real technology,
real science and real results - is the leading global aesthetic
device company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables physicians
to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite. The
Company sells its products under two distinct brands, Syneron and
Candela. With its innovative approach to aesthetic treatments,
Syneron has now entered into one of the largest in-demand
applications, skin lightening. Founded in 2000, the corporate,
R&D, and manufacturing headquarters for Syneron Medical Ltd.
are located in Israel. Syneron
also has R&D and manufacturing operations in the US. The
company markets and services and supports its products in 86
countries. It has offices in North
America, France,
Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide.
Additional information can be found at
http://www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
Contacts:
Jane Smith
Director of Marketing Communications, Candela Corporation
Office: +1-508-358-7637 Ext. 247; Mobile: +1-978-314-1053
jane.smith@candelalaser.com
Erin Carney
Senior Account Executive, Ruder Finn
Office: +1-212-593-6358; Mobile: +1-917-692-9166
carneye@ruderfinn.com